Kuratsune, H, Yamaguti, K, Takahashi, M et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 1994 · DOI
This study found that people with ME/CFS have lower levels of acylcarnitine, a substance that helps muscles produce energy, in their blood. Because acylcarnitine plays an important role in how muscles use energy, this deficiency might explain why ME/CFS patients experience fatigue, muscle pain, and weakness. Importantly, acylcarnitine levels tended to improve as patients recovered, suggesting it could be useful for tracking disease severity.
This research identifies a specific biochemical abnormality in ME/CFS that connects muscle symptoms to cellular energy metabolism, potentially providing both a biomarker for disease monitoring and a mechanistic target for future therapeutic interventions. Understanding the role of acylcarnitine deficiency could help explain the post-exertional malaise and exercise intolerance that significantly impact patients' quality of life.
This study does not prove that acylcarnitine deficiency causes ME/CFS symptoms—it only shows an association. The study cannot determine whether the deficiency is a primary cause, a consequence of the disease process, or secondary to reduced activity levels. Additionally, findings from a single timepoint cannot establish causality or definitively demonstrate the utility of acylcarnitine measurement in clinical practice without prospective validation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.